Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.

JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Published version of a preprint

Abstract

Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-24-3691

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 81 references

Research works printed but not linked: 2

  1. FDA, 2018, Multi-disciplinary review and evaluation NDA 210498
  2. Surveillance, Epidemiology and End Results Program (SEER), Cancer stat facts: cancer any site

Cited by

See all 17

Metadata

Authors
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., Sun, X., Wang, P., Ma, C., & Wang, Y.
Affiliations
  • 1Department of Pharmacology, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
  • 2Department of Translational Medicine, Jacobio (US) Pharmaceuticals, Inc., Burlington, Massachusetts.
  • Cleveland Clinic (US)
  • Washington University in St. Louis (US)
  • Mayo Clinic (US)
  • 6Department of Clinical Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
  • 7Department of Translational Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
  • 8Department of Medicinal Chemistry, Jacobio Pharmaceuticals Co., Ltd., Beijing, China.
  • 9Jacobio Pharmaceuticals Group Co., Ltd., Beijing, China.
Venue
Clinical Cancer Research
Published
2025-05-07
Volume
31
Issue
14
Pages
3019-3032
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4410156573
Cited by
17
References
81
Citations by year
2026: 15 · 2025: 2
FWCI
5.07
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
SHP2 inhibitors, allosteric inhibition, KRAS G12C, MEK inhibitors, EGFR inhibitors, anti-PD-1 therapy, combination therapy, acquired drug resistance, ERK1/2 phosphorylation, osimertinib resistance, non-small cell lung cancer
MeSH terms
Animals, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Signal Transduction, ras Proteins, Receptor Protein-Tyrosine Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-24-3691
The paper
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., Sun, X., Wang, P., Ma, C., & Wang, Y. (2025). JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-3691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.